Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro… - The lancet …, 2010 - thelancet.com
Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro… - The Lancet …, 2010 - infona.pl
The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown
to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 trial in patients …
to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 trial in patients …
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro… - The Lancet …, 2010 - Elsevier
BACKGROUND: The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen
has been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase …
has been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase …
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
G Masi, F Loupakis, L Salvatore, L Fornaro… - The Lancet …, 2010 - europepmc.org
Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro… - The Lancet …, 2010 - thelancet.com
Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
[PDF][PDF] Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro… - Lancet Oncol, 2010 - academia.edu
Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro… - THE LANCET …, 2010 - arpi.unipi.it
Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
G Masi, F Loupakis, L Salvatore, L Fornaro… - THE LANCET …, 2010 - iris.uniroma1.it
Abstract all patients were assessed for safety and efficacy. Median follow-up time was 28· 8
months (95% CI 24· 9-32· 5). PFS at 10 months was 74%(95% CI 62-85). Main grade 3 or 4 …
months (95% CI 24· 9-32· 5). PFS at 10 months was 74%(95% CI 62-85). Main grade 3 or 4 …
[引用][C] Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro… - The Lancet …, 2010 - cir.nii.ac.jp
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line
treatment for metastatic colorectal cancer: a phase 2 trial | CiNii Research CiNii 国立情報学 …
treatment for metastatic colorectal cancer: a phase 2 trial | CiNii Research CiNii 国立情報学 …
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore… - The Lancet …, 2010 - pubmed.ncbi.nlm.nih.gov
Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …